Overview

Toripalimab Combined With Axitinib as Neoadjuvant Therapy for Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma

Status:
Not yet recruiting

Trial end date:
2022-06-01

Target enrollment:

Participant gender:

Summary

This is a single-arm phase II clinical trial to evaluate the initial efficacy and safety of toripalimab combined with axitinib as neoadjuvant therapy for advanced/metastatic non-clear cell renal cell carcinoma

Phase:

Phase 2

Details

Lead Sponsor:

West China Hospital

Treatments:

Axitinib